Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients
- 1 January 1994
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 30 (1), 95-102
- https://doi.org/10.1007/bf00682744
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 1993
- A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.Journal of Clinical Oncology, 1992
- Specificity of Low Dose Fadrozole Hydrochloride (CGS 16949A) as an Aromatase InhibitorJournal of Clinical Endocrinology & Metabolism, 1991
- POTENCY AND SELECTIVITY OF THE NON-STEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST CANCER PATIENTSClinical Endocrinology, 1990
- THE EFFECTS OF CGS-16949A, AN AROMATASE INHIBITOR ON ADRENAL MINERALOCORTICOID BIOSYNTHESIS1990
- A phase I trial of CGS 16949a. A new aromatase inhibitorCancer, 1990
- PRELIMINARY-STUDY OF THE TREATMENT OF ADVANCED BREAST-CANCER IN POSTMENOPAUSAL WOMEN WITH THE AROMATASE INHIBITOR CGS-16949A1990
- Inhibition of Aromatase With CGS 16949A in Postmenopausal Women*Journal of Clinical Endocrinology & Metabolism, 1989
- A Randomized Trial Comparing Surgical Adrenalectomy with Aminoglutethimide plus Hydrocortisone in Women with Advanced Breast CancerNew England Journal of Medicine, 1981
- Aromatization of Androgens by Muscle and Adipose Tissue in Vivo*Journal of Clinical Endocrinology & Metabolism, 1978